Loading
SOPHiA GENETICS SA Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 05 Jun 2026.
SOPHiA GENETICS SA: what insiders have been doing
SOPHiA GENETICS SA, founded in 2011, is a Healthcare & Pharma company based in Boston, United States. Its directors and officers file their transactions with SEC (Form 4). From 18 October 2025 to 18 October 2026, the disclosure feed for SOPHiA GENETICS SA logged 196 filings by 20 insiders.
On the market, 1 insider bought (1 purchase totalling €85k) while 10 insiders sold (135 sales totalling €3.5M). The amount is not disclosed for 11 filings. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. One trade stands out by size: a sale of €291k from Camblong Jurgi, disclosed on 7 October 2026, or 0.052% of market capitalisation. Among those who bought: 1 finance chief.
The latest purchase dates back some time: it was published 134 days ago, on 5 June 2026. The median gap between a trade and its publication by SEC (Form 4) is 1 day. For comparison, the SEC allows two business days to file a Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification.
With 196 filings in twelve months, the company is more active than the median of 19 filings across the 5,811 companies we follow on the same exchange. Our records for SOPHiA GENETICS SA go back to 2026, with 1 purchase and 135 sales on the open market in total. On the fundamentals side, the SEC filing (20-F) for the period ending 31 December 2025 lists net income at -79.0 m USD.
Elsewhere in the same sector, our signals recently picked up insider purchases at Cooper Companies, Inc. and Anixa Biosciences Inc. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
196
Thresholds
n/a
Buy Volume
€85,239
1 ops. · all time
Sell Volume
€4M
135 ops. · all time
Who traded when
BuySaleJurgi Camblong32 sales
Zhenyu Xu25 sales
Philippe Menu20 sales
Ross Muken12 sales
Kevin Puylaert11 sales
Daan Van Well9 sales
+4 other insiders
Since the insiders bought
- +53.2%Entry US$5.28 · Close at T+90 US$8.09
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate SOPHiA GENETICS SA Strong Buy (bullish), based on 4 analysts. Average price target: US$9.75.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 19,589 of 24,148 companies
30.0
score / 100
Value16
Quality44
FCF yld-7.8%
Earn yld-14%
EV/EBITDA·
ROE-101%
Gross mgn67%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$7.06
Analyst consensus
4 analystsStrong buy
US$7.00Target US$9.75(+38%)US$14.00
Income statement
RevenueUS$77.3M
Gross profitUS$52.1M67% margin
EBITDA-US$63.4M-82% margin
Net income-US$79M-93.9% margin
Valuation
PER (forward)-14.1x
P/Book7.2x
Beta0.95
Balance sheet & cash
Market capUS$601M
Total debtUS$63M
Free Cash Flow-US$44.5M
Debt / Equity74%
Profitability & ownership
ROE-101.2%
ROA-24.5%
% insiders6.7%
% institutions62.4%
Last declaration on 14 October 2026
Declarations196 total
5,000 shares@ US$7.26060.0059% mcap8.5% of flowOrdinary SharesSEC:0001840706-26-000344:0
8,500 shares@ US$7.25540.010% mcap3.4% of flowOrdinary SharesSEC:0001840706-26-000340:0
6,168 shares@ US$8.12260.0080% mcap31.4% of flowOrdinary SharesSEC:0001840706-26-000336:0
4,240 shares@ US$8.13380.0055% mcap16.5% of flowOrdinary SharesSEC:0001840706-26-000335:0
5,284 shares@ US$8.12430.0068% mcap17.9% of flowOrdinary SharesSEC:0001840706-26-000334:0
185 shares@ US$8.060.0002% mcap24.5% of flowOrdinary SharesSEC:0001840706-26-000333:0
31 shares@ US$7.920.0000% mcap4.0% of flowOrdinary SharesSEC:0001840706-26-000333:1
1,592 shares@ US$8.10140.0021% mcap8.2% of flowOrdinary SharesSEC:0001840706-26-000332:0
7,394 shares@ US$8.12820.0096% mcap15.4% of flowOrdinary SharesSEC:0001840706-26-000331:0
40,172 shares@ US$8.12820.052% mcap18.9% of flowOrdinary SharesSEC:0001840706-26-000330:0
9,838 shares@ US$8.12880.013% mcap33.5% of flowOrdinary SharesSEC:0001840706-26-000328:0
6,168 shares@ US$8.070.0072% mcap52.3% of flowCommonSEC144:0001950047-26-010049
4,240 shares@ US$8.070.0050% mcap26.2% of flowCommonSEC144:0001950047-26-010044
1,592 shares@ US$8.070.0019% mcap40.7% of flowCommonSEC144:0001950047-26-010043
65,672 shares@ US$8.070.077% mcap24.2% of flowCommonSEC144:0001950047-26-010039
22,394 shares@ US$8.070.026% mcap51.5% of flowCommonSEC144:0001950047-26-010045
9,838 shares@ US$8.070.012% mcap58.1% of flowCommonSEC144:0001950047-26-010047
422 shares@ US$8.330.0005% mcap2.2% of flowOrdinary SharesSEC:0001840706-26-000317:0
774 shares@ US$8.330.0009% mcap4.4% of flowOrdinary SharesSEC:0001840706-26-000318:0
774 shares@ US$8.190.0009% mcap33.1% of flowCommonSEC144:0001950047-26-009710
422 shares@ US$8.190.0005% mcap5.9% of flowCommonSEC144:0001950047-26-009700
5,000 shares@ US$7.88330.0056% mcap11.6% of flowOrdinary SharesSEC:0001840706-26-000314:0
25 of 196 declarations
About SOPHiA GENETICS SA
SOPHiA GENETICS SA is a digital health company listed on the U.S. Nasdaq exchange (United States) under the ticker SOPH. Founded in 2011 by biologists, the company was built around a simple but ambitious goal: make complex medical data analysis more accessible and clinically useful. Its headquarters are in Rolle, Switzerland, with an established U.S. presence in Boston and additional international operations. For French-speaking investors, the business sits at the intersection of healthcare software, genomics, and AI-enabled precision medicine.
The company’s core asset is the cloud-native SOPHiA DDM™ platform, which analyzes genomic and multimodal data and converts it into actionable insights for hospitals, laboratories, and biopharma partners. SOPHiA GENETICS says more than 990 healthcare institutions use its platform across more than 75 countries, giving it a broad global footprint and an important network effect. Its main business lines include clinical genomics, oncology workflows, solid tumor testing, liquid biopsy applications, and collaborations with pharmaceutical companies for evidence generation, co-development, and companion-diagnostic-related work.
Read moreShow less
Competitively, SOPHiA GENETICS operates in a highly specialized market where software quality, clinical workflow integration, regulatory compliance, and dataset depth matter more than generic IT capabilities. The company differentiates itself through a cloud-native, consumption-based SaaS model rather than a one-off software sale. That positioning allows it to serve large academic hospitals, reference laboratories, and biopharma clients, while building recurring usage and long-term customer relationships.
Recent developments point to improving commercial momentum. In the first quarter of 2026, the company reported 22% year-over-year revenue growth, a record 108,000 genomic analyses performed on SOPHiA DDM™, and growth in its core genomics customer base to 537 customers. Management also highlighted stronger U.S. traction, including new wins with major health systems, alongside continued expansion in Europe. In May 2026, SOPHiA GENETICS announced a partnership with Synnovis in the U.K. to bring blood-based cancer testing to patients, and earlier in the year it disclosed a strategic collaboration with MD Anderson to accelerate AI-driven precision oncology.
From an investor perspective, the key attraction is the company’s combination of international growth, deeper penetration in the U.S. market, and potential operating leverage as platform usage scales. SOPHiA GENETICS is still in a growth-and-investment phase, but it is clearly focused on expanding its installed base, broadening its application suite, and moving gradually toward profitability.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
